Developer docs
API playgroundTry for free, no card

Search company profiles

Alcami

Full company profile

uuid000e3iv

Namestring
Alcami
Legal namestring
Alcami Corporation
Websiteurl
alcami.com
Company typeenum
Private
Founded yearint
1981
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersWilmington, United States
HQ citystring
Wilmington
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices15 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pharmaceutical contract manufacturing, sterile fill-finish services, oral solid dose manufacturing, analytical laboratory services, cGMP pharma storage
Industry5 codes
PRIMARYHLAGABAH
Sterile Fill-Finish & Aseptic Manufacturing CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAB
Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAJ
Packaging, Labeling & Serialization (Clinical/Commercial) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAC
Biologics (mAbs/Recombinant Proteins) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
NAICS code3 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Services-Commercial Physical & Biological Research8731
Product category
Pharmaceutical Contract Manufacturing (CDMO)
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Contract Development & Manufacturing (CDMO) Services
TypeProfessional Services
Description

Alcami generates revenue primarily through project-based contracts for integrated pharmaceutical manufacturing and development services, including sterile fill-finish, oral solid dose manufacturing, laboratory testing, and cGMP storage. Contracts are structured as multi-year service agreements or standalone project engagements, with pricing based on scope, scale, and complexity of manufacturing or testing requirements.

alcami.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Alcami is a U.S.-based Contract Development and Manufacturing Organization (CDMO) that provides fully integrated pharmaceutical services across three core pillars: Drug Product Manufacturing (sterile fill-finish, oral solid dose, packaging and labeling, formulation development), Laboratory Services (analytical method development, microbiology, compendial testing, biologics, extractables and leachables, nitrosamines, stability, ICP-MS), and cGMP Pharma Storage and Support Services (cryogenic storage, metrology and calibration, CQV, environmental monitoring, on-site services). The company serves pharmaceutical and biotech clients from preclinical development through commercial supply.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Supports production of over 80 commercial products worldwide
+4 more records
Product overview1 text field

Alcami is a U.S.-based Contract Development and Manufacturing Organization (CDMO) providing fully integrated pharmaceutical services across three core service pillars: Drug Product Manufacturing (sterile fill-finish, oral solid dose, packaging & labeling, and formulation development), Laboratory Services (analytical method development, microbiology, compendial testing, biologics, E&L testing, nitrosamines testing, stability storage, ICP-MS, and food interaction studies), and Pharma Storage & Services (cGMP storage, cryogenic storage, metrology & calibration, CQV, environmental monitoring, on-site services, and materials management). The company operates over 1 million square feet across the U.S. and Europe, supporting pharmaceuticals and biologics from preclinical development through commercial supply. The acquisition of Tjoapack in 2026 expanded their capabilities to include European Qualified Person (QP) release services and transatlantic packaging scale.

Product and service20 records
1Sterile Fill-Finish Manufacturing
CategoryDrug Product Manufacturing
2Oral Solid Dose Manufacturing
CategoryDrug Product Manufacturing
3Packaging & Labeling
CategoryDrug Product Manufacturing
4Formulation Development
CategoryDrug Product Manufacturing
5Analytical Method Development
CategoryLaboratory Services
6Microbiology Testing
CategoryLaboratory Services
7Compendial Testing
CategoryLaboratory Services
8Biologics Services
CategoryLaboratory Services
9Extractables & Leachables Testing
CategoryLaboratory Services
10Nitrosamines Testing
CategoryLaboratory Services
11Stability Testing & Storage
CategoryLaboratory Services
12ICP-MS Capabilities
CategoryLaboratory Services
13Food & Drug Interaction Studies
CategoryLaboratory Services
14cGMP Pharma Storage
CategoryPharma Storage & Services
15Cryogenic Storage
CategoryPharma Storage & Services
16Metrology & Calibration
CategoryPharma Storage & Services
17Commissioning, Qualification & Validation (CQV)
CategoryPharma Storage & Services
18Environmental Monitoring & Cleanroom
CategoryPharma Storage & Services
19On-Site Pharma Services
CategoryPharma Storage & Services
20Pharmaceutical Materials Management
CategoryPharma Storage & Services
Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2026-04-22
Description

Alcami agreed to acquire Tjoapack (announced April 2026, completed May 2026), a global contract packaging organization with facilities in the U.S. and the Netherlands. The acquisition creates an end-to-end global CDMO platform with U.S.-Europe supply chain redundancy. Tjoapack customers gain access to Alcami's drug product manufacturing, laboratory services, and pharma storage; Alcami customers gain expanded packaging scale, supply chain redundancy, and QP release services in Europe.

2Pacific Pharmaceutical Services
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-01-17
Description

Alcami acquired Pacific Pharmaceutical Services in January 2024 to enhance its West Coast presence and analytical testing capabilities. The acquisition added cGMP pharma storage and services on the West Coast, expanding Alcami's geographic network across the Northeast, Southeast, and West Coast of the U.S.

pehub.com
Recent move10 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Eurofins' CDMO arm provides pharmaceutical contract development, manufacturing, and laboratory services globally. Direct overlap with Alcami's analytical laboratory services, microbiology, and compendial testing offerings.

TypeBroad incumbent
Description

Catalent is the largest standalone CDMO globally, offering sterile fill-finish, oral solid dose, biologics, and softgel capabilities across a much broader network. Direct overlap with Alcami in sterile fill-finish and OSD makes it the most comparable scaled incumbent.

TypeBroad incumbent
Description

Lonza is the global leader in biologics CDMO and a major small-molecule API manufacturer. Direct competitor for Alcami's biologics analytical services and sterile fill-finish capacity, with materially greater scale and biologics depth.

TypeBroad incumbent
Description

Thermo Fisher's Patheon segment offers integrated drug substance, drug product, clinical trial materials, and packaging services globally. Overlaps with Alcami across nearly every service line and represents the type of large strategic that could be a future acquirer or competitor.

TypeDirect peer
Description

PCI is a closely comparable integrated CDMO focused on clinical and commercial packaging, sterile fill-finish, and global supply chain services. Direct overlap with Alcami's packaging, sterile fill-finish, and biopharma storage services, and similar in scale and PE-backed status.

TypeDirect peer
Description

Siegfried is a Swiss-listed CDMO providing API and finished drug product manufacturing (sterile and OSD) with similar mid-market positioning. Direct overlap with Alcami's small-molecule OSD and parenteral fill-finish services.

TypeBroad incumbent
Description

Samsung Biologics is a leading global biologics CDMO with large-scale mammalian cell culture capacity. Comparable to Alcami's growing biologics analytical and cell bank storage services, though substantially larger and more focused on biologics drug substance.

8Recipharm
TypeDirect peer
Description

Recipharm is a European-headquartered CDMO providing sterile fill-finish, OSD, and API services with global reach. Direct competitor for Alcami's Tjoapack-enabled European footprint and similar mid-market positioning.

TypeDirect peer
Description

Delpharm is a leading European CDMO providing sterile injectable and OSD manufacturing services across multiple sites. Comparable to Alcami's European operations post-Tjoapack and a competing option for European pharma clients.

TypeEmerging player
Description

Avid Bioservices is a mid-market biologics CDMO focused on mammalian cell culture, fill-finish, and process development. Alcami's Chief Strategy Officer previously served as Avid's CCO, indicating executive familiarity. Comparable mid-market CDMO with biologics focus.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

Integration3 records

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries3 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A4 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Alcami

Pharmaceutical Contract Manufacturing (CDMO)alcami.com

Alcami firmographics

Firmographics
Name
Alcami
Legal name
Alcami Corporation
Website
https://alcami.com
Company type
Private
Founded year
1981
Operating status
Operating
Headcount range
1–10 employees
Ownership category
akta.pro rank

Alcami industry classification

Industry
Product category
Pharmaceutical Contract Manufacturing (CDMO)
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGABAH
Sterile Fill-Finish & Aseptic Manufacturing CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAB
Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAJ
Packaging, Labeling & Serialization (Clinical/Commercial) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAC
Biologics (mAbs/Recombinant Proteins) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)

Keywords

  • Pharmaceutical contract manufacturing
  • Sterile fill-finish services
  • Oral solid dose manufacturing
  • Analytical laboratory services
  • CGMP pharma storage

Where Alcami is headquartered

Location

Headquarters

HQ city
Wilmington
HQ country
United States
HQ region
North America

Offices15 records

Markets served

Alcami business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales, Supply Chain

Revenue model

  1. Contract Development & Manufacturing (CDMO) Services: Alcami generates revenue primarily through project-based contracts for integrated pharmaceutical manufacturing and development services, including sterile fill-finish, oral solid dose manufacturing, laboratory testing, and cGMP storage. Contracts are structured as multi-year service agreements or standalone project engagements, with pricing based on scope, scale, and complexity of manufacturing or testing requirements.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Alcami product offering

Product offering

Core offering

Alcami is a U.S.-based Contract Development and Manufacturing Organization (CDMO) that provides fully integrated pharmaceutical services across three core pillars: Drug Product Manufacturing (sterile fill-finish, oral solid dose, packaging and labeling, formulation development), Laboratory Services (analytical method development, microbiology, compendial testing, biologics, extractables and leachables, nitrosamines, stability, ICP-MS), and cGMP Pharma Storage and Support Services (cryogenic storage, metrology and calibration, CQV, environmental monitoring, on-site services). The company serves pharmaceutical and biotech clients from preclinical development through commercial supply.

Product overview

Alcami is a U.S.-based Contract Development and Manufacturing Organization (CDMO) providing fully integrated pharmaceutical services across three core service pillars: Drug Product Manufacturing (sterile fill-finish, oral solid dose, packaging & labeling, and formulation development), Laboratory Services (analytical method development, microbiology, compendial testing, biologics, E&L testing, nitrosamines testing, stability storage, ICP-MS, and food interaction studies), and Pharma Storage & Services (cGMP storage, cryogenic storage, metrology & calibration, CQV, environmental monitoring, on-site services, and materials management). The company operates over 1 million square feet across the U.S. and Europe, supporting pharmaceuticals and biologics from preclinical development through commercial supply. The acquisition of Tjoapack in 2026 expanded their capabilities to include European Qualified Person (QP) release services and transatlantic packaging scale.

Differentiator

Problem solved

Functional benefit

Products and services

  • Sterile Fill-Finish Manufacturing
  • Oral Solid Dose Manufacturing
  • Packaging & Labeling
  • Formulation Development
  • Analytical Method Development
  • Microbiology Testing
  • Compendial Testing
  • Biologics Services
  • Extractables & Leachables Testing
  • Nitrosamines Testing
  • Stability Testing & Storage
  • ICP-MS Capabilities
  • Food & Drug Interaction Studies
  • cGMP Pharma Storage
  • Cryogenic Storage
  • Metrology & Calibration
  • Commissioning, Qualification & Validation (CQV)
  • Environmental Monitoring & Cleanroom
  • On-Site Pharma Services
  • Pharmaceutical Materials Management

Quantifiable outcome

  • Supports production of over 80 commercial products worldwide
  • +4 more outcomes

Companies that use Alcami

Customer profile

Segments3 records

Ideal customer profiles3 records

Alcami technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration3 records

Feature8 records

Alcami partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered flagship and core.

  • TjoapackflagshipStrategic or Co-development Partner · 22 April 2026Alcami agreed to acquire Tjoapack (announced April 2026, completed May 2026), a global contract packaging organization with facilities in the U.S. and the Netherlands. The acquisition creates an end-to-end global CDMO platform with U.S.-Europe supply chain redundancy. Tjoapack customers gain access to Alcami's drug product manufacturing, laboratory services, and pharma storage; Alcami customers gain expanded packaging scale, supply chain redundancy, and QP release services in Europe.
  • Pacific Pharmaceutical ServicescoreStrategic or Co-development Partner · 17 January 2024Alcami acquired Pacific Pharmaceutical Services in January 2024 to enhance its West Coast presence and analytical testing capabilities. The acquisition added cGMP pharma storage and services on the West Coast, expanding Alcami's geographic network across the Northeast, Southeast, and West Coast of the U.S.

Scale indicators10 records

Recent moves10 records

Expansion highlights6 records

Alcami competitors and assessment

Company assessment

Broad incumbents

  • Eurofins CDMO: Eurofins' CDMO arm provides pharmaceutical contract development, manufacturing, and laboratory services globally. Direct overlap with Alcami's analytical laboratory services, microbiology, and compendial testing offerings.
  • Catalent: Catalent is the largest standalone CDMO globally, offering sterile fill-finish, oral solid dose, biologics, and softgel capabilities across a much broader network. Direct overlap with Alcami in sterile fill-finish and OSD makes it the most comparable scaled incumbent.
  • Lonza Group: Lonza is the global leader in biologics CDMO and a major small-molecule API manufacturer. Direct competitor for Alcami's biologics analytical services and sterile fill-finish capacity, with materially greater scale and biologics depth.
  • Thermo Fisher Scientific (Patheon CDMO): Thermo Fisher's Patheon segment offers integrated drug substance, drug product, clinical trial materials, and packaging services globally. Overlaps with Alcami across nearly every service line and represents the type of large strategic that could be a future acquirer or competitor.
  • Samsung Biologics: Samsung Biologics is a leading global biologics CDMO with large-scale mammalian cell culture capacity. Comparable to Alcami's growing biologics analytical and cell bank storage services, though substantially larger and more focused on biologics drug substance.

Direct peers

  • PCI Pharma Services: PCI is a closely comparable integrated CDMO focused on clinical and commercial packaging, sterile fill-finish, and global supply chain services. Direct overlap with Alcami's packaging, sterile fill-finish, and biopharma storage services, and similar in scale and PE-backed status.
  • Siegfried Holding: Siegfried is a Swiss-listed CDMO providing API and finished drug product manufacturing (sterile and OSD) with similar mid-market positioning. Direct overlap with Alcami's small-molecule OSD and parenteral fill-finish services.
  • Recipharm: Recipharm is a European-headquartered CDMO providing sterile fill-finish, OSD, and API services with global reach. Direct competitor for Alcami's Tjoapack-enabled European footprint and similar mid-market positioning.
  • Delpharm: Delpharm is a leading European CDMO providing sterile injectable and OSD manufacturing services across multiple sites. Comparable to Alcami's European operations post-Tjoapack and a competing option for European pharma clients.

Emerging players

  • Avid Bioservices: Avid Bioservices is a mid-market biologics CDMO focused on mammalian cell culture, fill-finish, and process development. Alcami's Chief Strategy Officer previously served as Avid's CCO, indicating executive familiarity. Comparable mid-market CDMO with biologics focus.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Alcami social profiles

Digital presence

Alcami compliance and trust

Trust signal

Compliance2 records

Alcami financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Alcami leadership team

Management profile

Number of profiles

Profiles11 records

Alcami subsidiaries and ownership

Company hierarchy

Subsidiaries3 records

Alcami funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Alcami M&A and investment

M&A and investment

M&A4 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Alcami

What does Alcami do?

Alcami is a U.S.-based Contract Development and Manufacturing Organization (CDMO) that provides fully integrated pharmaceutical services across three core pillars: Drug Product Manufacturing (sterile fill-finish, oral solid dose, packaging and labeling, formulation development), Laboratory Services (analytical method development, microbiology, compendial testing, biologics, extractables and leachables, nitrosamines, stability, ICP-MS), and cGMP Pharma Storage and Support Services (cryogenic storage, metrology and calibration, CQV, environmental monitoring, on-site services). The company serves pharmaceutical and biotech clients from preclinical development through commercial supply.

Is Alcami a public or private company?

Alcami is a private company. It is classified as private equity controlled and is currently operating.

When was Alcami founded?

Alcami was founded in 1981. It employs 1 to 10 people.

Where is Alcami based?

Alcami is headquartered in Wilmington, United States, in the North America region.

How does Alcami make money?

One revenue line is on record: contract Development & Manufacturing (CDMO) Services.

Who are Alcami's main competitors?

Broad incumbents on record are Eurofins CDMO, Catalent, Lonza Group, Thermo Fisher Scientific (Patheon CDMO) and Samsung Biologics. Direct peers are PCI Pharma Services, Siegfried Holding, Recipharm and Delpharm. Avid Bioservices is listed as an emerging player.

Does Alcami have an API?

No public API is recorded for Alcami.

What industry is Alcami in?

Alcami's product category is Pharmaceutical Contract Manufacturing (CDMO). Its primary akta.pro industry code is HLAGABAH, Sterile Fill-Finish & Aseptic Manufacturing CDMO, with a secondary code of HLAGABAB, Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business & FinancialAlcami Announces Promotion of Robert Tragas to Vice President, Laboratory ServicesAlcami promoted Robert Tragas to Vice President of Laboratory Services, expanding his role to lead laboratory operations across its Research Triangle Park campus. He will oversee analytical, biologics, microbiology, and environmental monitoring functions, with leadership focused on alignment and growth. The promotion aims to support scaling biologics capabilities amid growing demand.News-MedicalAlcami announces promotion of Robert Tragas to Vice President, Laboratory ServicesAlcami promoted Robert Tragas to Vice President of Laboratory Services, where he will lead laboratory operations across its Research Triangle Park campus. He joined the company over 26 years ago and will focus on operational excellence and growth as biologics demand rises.AInvestThe CDMO Build-Out No One Is Watching: Why Alcami's Tennessee Expansion Is a Supply Chain SignalAlcami, a U.S.-based contract development and manufacturing organization, announced on June 19th a major expansion of its Tennessee facility, adding a new high-speed bottle packaging line expected to be operational in the first half of 2027, alongside upgraded quality systems and temperature-controlled storage capacity. The expansion follows Alcami's April 2026 acquisition of Tjoapack, which brought European Qualified Person oversight and U.S. supply chain redundancy, and builds on December 2025 network-wide additions of five sterile fill-finish lines and GMP storage. The investment reflects a strategic bet on the global pharmaceutical contract manufacturing market projected to reach $312 billion by 2030, growing at an 8.2% compound annual rate, driven by reshoring dynamics and structural demand from biotech pipeline outsourcing.PR NewswireAlcami Expands Quality, Packaging, and Storage Capabilities at Tennessee FacilityAlcami Corporation announced strategic and operational investments at its Tennessee facility, which was added to its network through the recent acquisition of Tjoapack. The investments include integrating the site into Alcami's enterprise-wide Quality Management System using MasterControl, restructuring Quality and Operations teams, upgrading packaging lines with serialization capabilities, and adding a new high-speed bottle packaging line expected to be operational in the first half of 2027. The company is also expanding GMP temperature-controlled storage capacity as part of its broader integration strategy to enhance operational efficiency, flexibility, and continuity of supply for growing customer demand.MorningstarAlcami Expands Quality, Packaging, and Storage Capabilities at Tennessee FacilityAlcami is investing in its Tennessee facility, integrating it into its Quality Management System and upgrading packaging lines with serialization capabilities. A new high-speed bottle packaging line is expected to be operational in the first half of 2027, expanding capacity and throughput.ContractpharmaAlcami Announces Strategic & Operational Investments at Tennessee FacilityAlcami Corporation, a contract development and manufacturing organization (CDMO), announced strategic and operational investments at its Tennessee facility, which was added to its network through the acquisition of Tjoapack. The investments include integrating the site into Alcami's enterprise-wide Quality Management System using MasterControl, restructuring Quality and Operations teams, upgrading packaging lines with increased speeds and serialization capabilities, and adding a new high-speed bottle packaging line expected to be operational in the first half of 2027. The company is also expanding its GMP storage network with temperature-controlled capacity to enhance operational efficiency, supply continuity, and product protection for growing customer demand.StartseiteAlcami Completes Tjoapack Acquisition to Bolster Global Packaging ScaleAlcami, a US-based contract development and manufacturing organization (CDMO), has completed its acquisition of Tjoapack, a leading global contract packaging organization with facilities in the United States and the Netherlands. The combined organization now employs over 1,400 personnel across more than 1 million square feet of operational footprint and supports production of more than 80 commercial products worldwide. The integration aims to expand end-to-end CDMO capabilities across the US and Europe, with customers gaining access to broader drug product manufacturing, laboratory services, and QP release services.PR NewswireAlcami Completes Acquisition of TjoapackAlcami Corporation, a U.S.-based contract development and manufacturing organization (CDMO), has completed its acquisition of Tjoapack, a global contract packaging organization with facilities in the United States and The Netherlands. The combined organization now employs over 1,400 personnel across more than 1 million square feet of operational space and supports production of over 80 commercial products worldwide. The acquisition strengthens Alcami's packaging scale and supply chain redundancy while expanding end-to-end CDMO capabilities across the U.S. and Europe, with CEO Patrick Walsh assuming leadership of the integrated companies.BioSpaceAlcami Completes Acquisition of TjoapackAlcami completed its acquisition of Tjoapack, a global contract packaging firm, combining over 1,400 employees and more than 1 million square feet of facilities. The deal expands Alcami's CDMO capabilities across the U.S. and Europe, with CEO Patrick Walsh leading the combined organization.openPR.comLeading Companies Fueling Innovation and Growth in the Investigational New Drug Contract Development and Manufacturing Organization (CDMO) MarketThe investigational new drug contract development and manufacturing organization (CDMO) market is projected to reach $8.17 billion by 2030, growing at a compound annual growth rate of 6.6%, driven by scaling up of gene and cell therapy manufacturing capacity, rising demand for monoclonal antibodies and recombinant proteins, and increasing global collaborations in biotechnology research. In January 2024, US-based pharmaceutical CDMO Alcami Corporation acquired Pacific Pharmaceutical Services to enhance its West Coast presence and analytical testing capabilities. In August 2023, Germany-based Sartorius AG partnered with US-based Repligen Corporation to introduce an integrated upstream bioprocessing system combining BIOSTAT STR and XCell ATF technologies for biopharmaceutical manufacturing.